{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-066355","form_type":"8-K","ticker":"AMLX","cik":"0001658551","company_name":"Amylyx Pharmaceuticals, Inc.","filed_at":"2025-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.233546+00:00","generated_at":"2026-05-22T04:42:28.952240+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Amylyx Q1 net loss $35.9M, cash $204.1M; avexitide Phase 3 underway","bullets":["Q1 net loss $35.9M ($0.42/share), down from $118.8M ($1.75/share) YoY on lower R&D and SG&A costs.","Cash, equivalents, and marketable securities $204.1M; cash runway expected through end of 2026.","Phase 3 LUCIDITY trial of avexitide in PBH dosed first patient; enrollment complete 2025, topline data H1 2026.","Phase 1 LUMINA trial of AMX0114 (ASO for ALS) dosed first patient; early cohort data expected in 2025.","Closed $65.5M public offering of 19.7M shares in Jan 2025; Phase 2b ORION (PSP) data expected Q3 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-066355","json":"https://secwatch.observer/filing/0000950170-25-066355.json","markdown":"https://secwatch.observer/filing/0000950170-25-066355.md","text":"https://secwatch.observer/filing/0000950170-25-066355.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1658551/000095017025066355/0000950170-25-066355-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1658551/000095017025066355/amlx-20250508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T04:42:28.952240+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}